Janssen Search
Search results
Elizabeth Forminard
ELIZABETH FORMINARD General Counsel Pharmaceuticals Liz Forminard is General Counsel, Pharmaceuticals and is responsible for legal matters relating to the Pharmaceuticals Group globally. In addition, the Legal group providing support to Johnson & ...
Richard (Dick) Insel, M.D.
RICHARD (DICK) INSEL, M.D. GLOBAL HEAD HEALTHY BABY INITIATIVE WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Healthy Baby Initiative, World Without Disease Accelerator (WWDA), Dick is leading a strategy focused on changing the trajectory of health for ...
Discovery & Development
Discovery & Development Our portfolio is fueled by our world-class discovery and development teams and external collaborators. We continue to work to deliver innovative solutions that contribute to the global fight against infectious diseases and ...
Janssen Immunology R&D – ACG 2020 Newsroom
Welcome to the Janssen Immunology ACG 2020 Newsroom! Please see below for the latest meeting news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for Inflammatory Bowel ...
Emmanuelle Quilès
EMMANUELLE QUILÈS WORLDWIDE VICE PRESIDENT CARDIOVASCULAR, METABOLISM AND PULMONARY HYPERTENSION JANSSEN GLOBAL COMMERCIAL STRATEGY ORGANIZATION (GCSO) Emmanuelle Quilès is Worldwide Vice President, Cardiovascular, Metabolism and Pulmonary Hypertension. ...
Candice Long
CANDICE LONG WORLDWIDE VICE PRESIDENT IMMUNOLOGY Candice Long is the Worldwide Vice President for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology Research & Development ...
Products and Packaging
Products and Packaging We’re committed to delivering the highest quality products for patients, doctors and customers, while also working to reduce our environmental footprint. Our approach includes integrating sustainable design solutions into our ...
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Aug 27, 2024 Belgium Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI [1], [2], [3], [4] Amivantamab ...
Building a Compassionate Culture that Supports Caregivers in the Workplace and Beyond
Building a Compassionate Culture that Supports Caregivers in the Workplace and Beyond At the Janssen Pharmaceutical Companies of Johnson & Johnson, we recognize all those who assume the responsibility of caring for a loved one with a serious illness ...
Outpacing AMR Infections Through Innovations
Outpacing AMR Infections Through Innovations As scientists in the field of infectious diseases, it is our life’s work to research and develop solutions to some of the world’s most challenging and dangerous health concerns. While we have made tremendous ...